Zelzate, Belgium

Jelle Cornelus

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: University of Ghent. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jelle Cornelus. Retrieved from https://idiyas.com/inventor/jelle-cornelus-q1hixdf8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jelle Cornelus and Peloruside Analogs.

Introduction

Jelle Cornelus is an inventor associated with Zelzate, Belgium, and the University of Ghent. His work includes a patent for therapeutic compounds inspired by peloruside, a naturally occurring substance.

Latest Patents

Cornelus is named on one patent, 1 patent, titled “Peloruside Analogs.” The invention describes phenyl analogs of naturally occurring peloruside for treating diseases caused or influenced by microtubule stability, including proliferative diseases. The analogs are designed to be easier to synthesize, potentially enabling production in larger quantities for therapeutic use.

Career Highlights

The patent reflects research focused on developing more accessible synthetic compounds with potential therapeutic applications. Cornelus is associated with the University of Ghent.

Collaborations

His listed coworkers include Johan Van Der Eycken and Nick Jacobs. Their names are associated with the collaborative research behind the patent.

Conclusion

Jelle Cornelus’s patent on peloruside analogs highlights an effort to make promising therapeutic compounds easier to synthesize and produce at scale.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…